FDA's Bold Move: Single Study Approval for New Drugs
FDA's Bold Move: Single Study Approval for New Drugs is drawing significant interest across the industry.
The FDA plans to drop its requirement for two studies to approve new drugs, aiming to speed up the availability of medicines. Under Commissioner Dr. Marty Makary, the new policy will rely on a single study, combined with supporting evidence, reflecting scientific advancements and emphasizing speed and flexibility.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Sonata Software's US Subsidiary Files Legal Proceedings to Recover USD 10.64 Million in Outstanding Receivables
- Junior and Princess Andre 'sign up for Celebrity Race Across the World'
- Anurag Dobhal Instagram Live Sparks Concern Over Mental Health
- Libra Horoscope Today, February 14, 2026: A new friend may enter your life
Source: Original →